-
1 Comment
From a valuation standpoint, the stock is 482.8% more expensive than other stocks from the Other sector with a price to sales ratio of 5.4.
Based on the above factors, Adicet Bio, Inc gets an overall score of 0/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
Sector | Healthcare |
Industry | Biotechnology |
ISIN | US0070021086 |
Target Price | 6.4 |
---|---|
Market Cap | 50M |
PE Ratio | None |
Beta | 1.65 |
Dividend Yield | None |
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ACET using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025